Evangelos V. Badiavas, Ph.D., M.D. Inventor, Founder, Chief Scientific Officer

Aegle’s research team is headed by Dr. Badiavas—a board certified dermatologist and dermatopathologist—whose research has been focused on wound healing, bone marrow, stem cells, bioengineered skin, dermatology, and translational research for more than 30 years. Dr. Badiavas was among the first to describe the trafficking and engraftment of bone marrow cells to wounded skin, and the restoration of skin structures by bone marrow stem cells. He has been the principal investigator on protocols delivering stem cells to wounds for more than 15 years and was the first to describe the delivery of bone marrow stem cells to chronic wounds in humans. Dr. Badiavas has been awarded three IND’s by the FDA for the delivery of stem cells to patients. Having worked in this area for years, he is well versed in all recent regulatory aspects of cell-based therapeutics. His expertise in bone marrow stem cells began as a graduate student in 1982 when he worked on erythroid progenitors under the direction of Alan Erslev, Jaimie Caro and Hideko Kaji. Since then, Dr. Badiavas has completed his PhD, postdoctoral training, medical school, dermatology residency, and dermatopathology fellowship.. He is a practicing dermatologist and dermatolopathologist with more than 20 years experience with particular interests in the histologic evaluation of wounds. He has been working with bioengineered skin materials for more than 25 years and has described several key histological features associated with the application of these materials to patients. Dr. Badiavas has also published and presented his findings in several preclinical studies for wounds including rodent and pig models. He has served as a consultant, NIH study section member, and moderator for wound based and stem cell projects. Dr. Badiavas has an extensive and diverse history of close collaboration with several highly regarded stem cell, bone marrow, and wound healing investigators. His unique training and experience allows him to comfortably move between these sometimes-distinct fields.




Stephen C. Davis, Co-Inventor, Founder

Steve Davis is co-founder of Aegle Therapeutics. He is a Research Professor at the University of Miami Miller School of Medicine in the Department of Dermatology & Cutaneous Surgery. He is the Director of the Pre-Clinical Wound Healing & Infection Research Laboratories in the department and has over 30 years experience using various wound healing and infection models. He works with a large number of companies in research and development of various products that are on the market today, e.g. DuoDerm® dressing, Kerlix A.M.D.®, Liquid Bandage®. He has several book chapters and over 100 published articles and abstracts on wound healing and infection. For the past several years he has been funded by DARPA, Canadian Defense, US Army, Office of Naval Research, NSF and the NIH.




Shelley A. Hartman, Chief Executive Officer

Shelley Hartman joined Aegle Therapeutics in August of 2014 during which time she served as an Entrepreneur-in-Residence at The University of Miami Miller School of Medicine. Prior to Aegle, Ms. Hartman served for nine years as CEO of LifeSync Corporation, a start-up medical device company developing and marketing wireless medical technology to hospital customers. LifeSync was spun-off from LifeSync Holdings (f/k/a GMP Companies, Inc.), a development company focused on biopharmaceutical and medical device product development. Prior to LifeSync, Ms. Hartman served for more than 18 years in the investment banking industry, most recently as Managing Director in the Healthcare Department of the Investment Banking Division at Goldman, Sachs & Co. Ms. Hartman currently serves as Chairman of LifeSync Holdings, Inc. and as a member of the Advisory Council for Zenith Education Group.




Robert Ryan

Dr. Robert Ryan is currently the President and CEO of Innova Therapeutics, a company focused on developing innovative therapies for diseases with high unmet needs.


Dr. Ryan has more than 27 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV. Prior to Innova Therapeutics, Dr. Ryan was the President and CEO of Scioderm, a company he co-founded in 2013. Dr. Ryan led the development of SD-101, a topical therapy for Epidermolysis Bullosa, progressing from pre-IND stage to an ongoing single Phase 3 US/Europe registration study in less than 2 years. Scioderm was the first biotech to receive “Breakthrough Therapy” designation from the FDA. In September 2015, Dr. Ryan led a deal to sell Scioderm to Amicus Therapeutics, with upfront payments and milestones totaling approximately $957 million.


Dr. Ryan’s diverse pharmaceutical career covered senior preclinical, regulatory and clinical activities with Roche, Bristol-Myers Squibb (BMS), UCB, Atherogenics, and Pfizer. In addition Dr. Ryan previously held senior regulatory positions at three of the top five leading CRO’s, PPD, INC Research, and Quintiles. While at Quintiles, Dr. Ryan served as the Chief Regulatory Officer for PharmaBio due diligence team, which was the corporate ventures group that focused on innovative partnering opportunities with pharmaceutical and biotech companies. Selected investment opportunities resulted in investment in excess of $800 million, with a 100% successful track record on deals completed. Prior to working in the pharmaceutical/biotech industry, Dr. Ryan conducted research for several years at the National Institutes of Health's environmental division. Dr. Ryan graduated with a doctorate degree in Toxicology from the University of North Carolina at Chapel Hill, and is board certified in Toxicology. In addition, Dr. Ryan has advanced degreesin Genetics and Pharmacokinetics.




Robert Williamson, Founder, Chief Financial Officer

Bob Williamson helped found Aegle in 2013. During his career he started, funded, managed, and/or was a director of over a dozen new companies ranging from the most esoteric medical technologies to industrial valves. He founded venture capital funded Data Net Corporation and was the CFO of Equinox Systems (NASDAQ-EQNX) where he managed its successful purchase by Avocent Corporation. He has served on numerous non-profit boards and currently is a director and treasurer of the St. Martha Concert® series. He has a BS-Engineering and MBA from Stanford.




Robert Williamson III

Robert F. Williamson, III is the CEO of privately held PharmAkea, a fibrosis drug development company financed through a build-to-buy partnership with Celgene (NASDAQ: CELG) and is Director of privately held Naia Limited, a global drug development company. He has been active in starting and assisting public and private companies through his consultancy, LaSalle Venture Advisers. Previously, as a Director, he helped finance, grow, take public and sell Pharmasset, Inc. (NASDAQ: VRUS), which was bought by Gilead (NASDAQ:GILD) for $11B. He was also appointed to the board of Progen Pharmaceuticals (NASDAQ: PGLA) after he sold CellGate to Progen, and has been on numerous private company boards. Earlier, Mr. Williamson was Chief Executive Officer of Arriva Pharmaceuticals, President and Chief Operating Officer of Eos Biotechnology - which he sold to Protein Design Labs (NASDAQ: PDLI), and Chief Operating Officer of Pangea / DoubleTwist, Inc. - which was acquired in part by Merck (NYSE: MRK) and Hitachi (NYSE: HIT). Before managing life sciences companies, Mr. Williamson was a partner with The Boston Consulting Group, Inc., and his clients included top pharmaceutical, medical device and health care companies with additional clients in high technology and energy. Mr. Williamson started his career as a research assistant for the Federal Reserve Board of Governors in Washington, D.C. where he supported monetary policy under Alan Greenspan. He received a B.A. in Economics from Pomona College and an M.B.A. from Stanford Graduate School of Business.